Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
IBD Center, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy.
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):211-213. doi: 10.1038/s41575-021-00420-w.
Data on the efficacy and safety of SARS-CoV-2 vaccines are now available, but evidence for these vaccines in those who are immunocompromised (including patients with inflammatory bowel diseases) are lacking. As vaccination begins, questions on advantages and disadvantages can be partially addressed using the experience from other vaccines or immune-mediated inflammatory disorders.
目前已有关于 SARS-CoV-2 疫苗的疗效和安全性的数据，但这些疫苗在免疫功能低下人群（包括炎症性肠病患者）中的证据尚缺乏。随着疫苗接种的开始，使用其他疫苗或免疫介导的炎症性疾病的经验，可以部分解决其优缺点问题。
